Catalyst Pharmaceuticals files new drug application with FDA
Catalyst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration, bringing the Coral Gables-based drug maker one step closer to launching Firdapse, a treatment for a rare degenerative neuromuscular disease.
Founded in 2002, Catalyst (Nasdaq: CPRX) has been working to develop Firdapse for almost a decade, a common timeline in the highly regulated pharmaceutical industry.
Firdapse aims to treats symptoms of Lambert-Eaton myasthenic syndrome, a degenerative…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Debora Lima Source Type: news
More News: Brain | Food and Drug Administration (FDA) | Health Management | Myasthenia Gravis | Neurology | New Drug Applications